Abstract
Studies were conducted to examine the functional role of the nucleotide-binding domains of MRP in drug resistance and drug transport in isolated membrane vesicles. In vivo studies were conducted by preparing stable transfectants of HeLa cells with wild-type MRP cDNA or MRP cDNAs which had been mutated at certain nucleotide binding domains (NBD). Stable transfectants producing equivalent amounts of the MRP encoded protein P190 were used in this study. The results demonstrated that deletions in the C-motif of NBD1 or the A-motif of NBD2 have a pronounced effect in reducing resistance levels to chemotherapeutic agents. Certain single-site mutations in lysines in these same motifs also reduce IC50 values. It has also been observed that mutation of the MRP NBDs results in an increase in drug accumulation and a reduction in drug efflux. Additional studies have been carried out in which recombinant baculovirus containing either wild-type MRP or MRP containing mutated NBDs was prepared and used to infect SF21 insect cells. Using this system we have analyzed the effects of these mutations on in vitro transport of leukotriene C4 (LTC4) 17 ß-estradiol 17 (ß-D-glucuronide)(E217ßG) and daunomycin in membrane vesicles prepared from baculovirus infected cells. The results demonstrate that deletions and site-specific mutations in MRP NBDs greatly reduce the ATP dependent transport of all three substrates. The results of these studies conducted both in vivo and in vitro demonstrate that the NBDs of MRP function in a cooperative manner and are critical for the transport activity of the MRP encoded protein P190. These studies also identify specific lysines in NBD1 and NBD2 which are important for optimal MRP activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC and Deeley RG (1995) Characterization of the Mr 190 000 multidrug resistance protein ( MRP) in drug-selected and transfected human tumor cells. Cancer Res 55: 102–110.
Ambudkar SV, Lelong IH, Zhang J, Cardareli CO, Gottesman MM and Pastan I (1992) Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drugstimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89: 8472–8476.
Azzaria M, Schurr E and Gros P (1989) Discrete mutations introduced in the predicted nucleotide-binding sites of the mdrl gene abolish its ability to confer multidrug resistance. Mol Cell Biol 9: 5289–5297.
Barrand MA, Robertson KJ, Neo S-Y, Rhodes T, Wright KA, Twentyman PR and Scheper RJ (1995) Localization of the multidrug resistance-associated protein MRP in resistant large-cell lung tumour cells. Biochem pharmacol 50: 1725–1729.
Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC) 258: 1650–1654.
Cole SPC, Sparks ICE and Fraser K (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910.
Coley HM, Workman P and Twentyman PR (1991) Retention of activity by selected anthracyclines in a multidrug resistant human large cell carcinoma line without P-glycoprotein hyperexpression. Br J Cancer 63: 351–357.
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG (1994) Overexpression of multidrug resistance-associated protein ( MRP) increases resistance to natural product drugs. Cancer Res 54: 357–361.
Gros P, Neriah YB, Croop JM and Hansman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728–731.
Hamada H and Tsuruo T (1988) Purification of the 170– to 180kilodalton membrane glycoprotein associated with multidrug resistance–170 to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 263: 1454–1458.
Jedlitschky G, Leier I, Bucholz U, Center MS and Keppler D (1994) ATP dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833.
Krishnamachary N and Center MS (1993) The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190kDa membrane bound glycoprotein. Cancer Res 53: 3658–3661.
Krishnamachary N, Ma L, Zheng L, Safa AR and Center MS (1994) Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res 6: 119–127.
Kruh GD, Chan A, Myers K, Gaughan K, Miki T and Aaronson SA (1994) Expression completmentary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 54: 1649–1652.
Lautier D, Canitrot Y, Deeley RG and Cole SPC (1996) Multidrug resistance mediated by the multidrug resistance protein ( MRP) gene. Biochem Pharmacol 52: 967–977.
Leier I, Jedlitschky G, Bucholz U, Cole SPC, Deeley RG and Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugate. J Biol Chem 269: 27807–27810.
Leier I, Jedlitschky G, Bucholz U, Center M, Cole SPC and Dee-ley RG (1996) ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314: 433–437.
Loe DW, Deeley RG and Cole SPC (1996) Biology of the multidrug resistance-associated protein, MRP. European J Cancer 32A: 945–957.
Loe WL, Almquist KC, Deeley RG and Cole SPC (1996) Multidrug resistance protein (MRP) mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. J Biol Chem 271: 9675–9682.
Ma L, Krishnamachary N and Center MS (1995) Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338–3343.
Marquardt D, McCrone S and Center MS (1990) Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50: 1426–1430.
Marsh W, Sicheri D and Center MS (1986) Isolation and characterization of adriamycin-resistant HL60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res 46: 4053–5057.
McGrath T, Latoud C, Arnold ST, Safa AR, Felsted RL and Center MS (1989) Mechanisms of multidrug resistance in HL60 cells: analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem Pharmacol 38: 3611–3619.
Muller M, Meijer C, Zaman GJR Borst B, Scheper RJ, Mulder NH, De Vries EGE and Jansen PLM (1994) Overexpression of the gene encoding the multidrug resistance associated protein results in increased ATP dependent glutathione S-conjugate transport (1994) Proc Natl Acad Sci USA 91: 13033–13037.
Sanger F, Nicklin S. and Coulson AR (1977) Sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74: 5466–5466.
Saptarshi P, Belinsky MG, Shen H and Kruh GD (1996) Structure and In vitro substrate specificity of the murine multidrug resistance-assoicated protein. Biochemistry 35: 13647–13655.
Shimabuka AM, Nishimot T, Ueda K and Komano T (1992) P-glycoprotein ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem 267: 4308–4311.
Sun H, Zhu Q and Center MS (1996) Expression and characterization of the multidrug resistance-associated protein in insect cells infected with a recombinant baculoviurs. Oncol Res 8: 287–293.
Versantvoort CHM, Broxterman HJ, Pinedo HM, de Vries EGE, Feller N, Kuiper CM and Lankelma J (1992) Energy dependent processes involved in reduced drug accumulation in multidrugresistant lung cancer cell lines without P-glycoprotein expression. Cancer Res 52: 17–23.
Walker JE, Saraste M, Runswick MJ and Gay NJ (1982) Distantly related sequences in the a-and ß-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1: 945–951.
Zaman GJR, Flens MJ, van Leusden MR De Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822–8826.
Zhu Q, Sun H and Center MS (1997) Functional analysis of the nucleotide binding domains of the multidrug resistance protein MRP. Oncol Res 9: 229–236.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Center, M.S., Zhu, Q., Sun, H. (1998). Mutagenesis of the putative nucleotide-binding domains of the multidrug resistance associated protein (MRP). Analysis of the effect of these mutations on MRP mediated drug resistance and transport. In: Clynes, M. (eds) Multiple Drug Resistance in Cancer 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-2374-9_3
Download citation
DOI: https://doi.org/10.1007/978-94-017-2374-9_3
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5108-0
Online ISBN: 978-94-017-2374-9
eBook Packages: Springer Book Archive